Full Paper
Synthesis of 1,2-Bis(bromomethyl)-4,5-dimethylbenzene (4)
as that used to make the methyl o-xylene-substituted full-
erene derivatives from 3. DM_OXCMA: 1H NMR
(300 MHz, CDCl3, d): 7.42 (s, 2H), 4.76 (d, 2H), 4.37 (d,
2H), 2.44 (s, 6H); 13C NMR (75 MHz, CDCl3/CS2, d):
161.08, 158.56, 157.87, 157.65, 148.88, 148.51, 147.87,
147.54, 146.46, 146.13, 145.77, 144.51, 144.20, 143.63,
143.09, 142.91, 142.44, 142.03, 141.63, 141.33, 141.03,
139.83, 138.36, 128.36, 64.65, 43.11, 43.06, 20.63; MALDI-
TOF MS (M+1, C70H12): calcd, 852.09; found, 852.17;
purity: 99.3% by HPLC. DM_OXCBA: 1H NMR
(300 MHz, CDCl3, d): 7.67–7.03 (m, 4H), 4.92–3.82 (m,
8H), 2.66–1.93 (m, 12H); 13C NMR (75 MHz, CDCl3, d):
162.54, 157.26, 156.56, 153.51, 152.69, 148.42, 146.56,
146.10, 145.73, 145.16, 144.87, 144.57, 144.32, 144.12,
144.06, 143.87, 143.23, 142.68, 142.54, 141.12, 138.75,
138.12, 137.87, 128.32, 127.43, 64.21, 63.77, 45.53, 44.87,
20.15, 19.87; MALDI-TOF MS (M+1, C80H26): calcd,
986.20; found, 986.73; purity: 98.8% by HPLC. DM_
Compound 4 (4.17 g, 79.1%) was prepared from 2 via the
same procedure as that used to make 3. 1H NMR
(300 MHz, acetone-d6, d): 7.24 (s, 2H), 4.76 (s, 4H), 2.24
(s, 6H); 13C NMR (75 MHz, CDCl3, d): 137.33, 134.87,
132.42, 30.47, 19.23.
Synthesis of M_OXCMA, M_OXCBA, and M_OXCTA
Compound 3 (1.52 g, 5.52 mmol), KI (1.38 g, 8.34 mmol),
18-crown-6 (3.64 g, 13.8 mmol), and C60 (1.0 g, 1.39 mmol)
were dissolved in anhydrous 1,2-dichlorobenzene at
reflux for 48 h under an argon atmosphere and dark con-
ditions. Upon cooling to room temperature, the crude
product was precipitated by adding methanol. The result-
ing solid was purified using column chromatography on
silica gel with toluene/hexane as the eluent. This separa-
tion yielded M_OXCMA (130 mg, 11.2%), M_OXCBA
(269 mg, 20.3%), and M_OXCTA (261 mg, 17.5%).
M_OXCMA: 1H NMR (300 MHz, CDCl3, d): 7.57 (d,
1H), 7.49 (s, 1H), 7.37 (d, 1H), 4.76 (d, 2H), 4.40 (d, 2H),
2.49 (s, 3H); 13C NMR (75 MHz, CDCl3/CS2, d): 157.65,
157.37, 149.36, 149.17, 148.65, 148.26, 147.89, 147.55,
147.13, 146.56, 146.22, 145.86, 144.75, 144.52, 143.67,
143.29, 143.07, 142.92, 142.56, 142.31, 142.16, 141.72,
139.92, 137.53, 128.87, 127.56, 65.93, 46.53, 45.22, 21.32;
MALDI-TOF MS (M+1, C69H10): calcd, 838.08; found,
1
OXCTA: H NMR (300 MHz, CDCl3, d): 7.62–6.88 (m,
6H), 4.71–3.65 (m, 12H), 2.56–1.88 (m, 18H); 13C NMR
(75 MHz, CDCl3, d): 162.31, 155.46, 152.23, 150.93,
150.32, 149.40, 146.87, 146.23, 145.64, 145.33, 144.59,
144.23, 143.67, 143.20, 142.66, 142.36, 142.07, 141.71,
141.26, 140.92, 140.67, 140.15, 139.77, 139.16, 138.73,
138.55, 138.32, 136.12, 135.78, 134.96, 129.57, 128.35,
128.23, 127.51, 65.17, 67.57, 66.82, 65.77, 64.52, 64.22,
63.67, 63.18, 46.17, 45.82, 44.35, 43.87, 42.21, 42.07, 20.15,
20.01, 19.96; MALDI-TOF MS (M+1, C90H38): calcd,
1118.30; found, 1118.57; purity: 98.4% by HPLC.
1
838.21; purity: 99.2% by HPLC. M_OXCBA: H NMR
(300 MHz, CDCl3, d): 7.87–7.07 (m, 6H), 4.92–3.21 (m,
8H), 2.62–2.03 (m, 6H); 13C NMR (75 MHz, CDCl3, d):
157.52, 156.16, 151.59, 150.07, 147.55, 147.17, 146.89,
146.13, 146.06, 145.92, 145.71, 145.58, 145.42, 144.83,
144.35, 143.76, 143.58, 143.35, 143.14, 139.35, 138.66,
138.38, 137.22, 128.92, 128.43, 128.07, 66.84, 65.78, 65.06,
64.76, 64.12, 47.41, 46.27, 45.53, 22.54, 22.32, 21.87, 21.56;
MALDI-TOF MS (M+1, C78H22): calcd, 958.17; found,
4.3. Measurements
1H and 13C NMR spectra were recorded using a Varian
300 spectrometer. MALDI-TOF mass spectra were mea-
sured using a ZMS-DX303 mass spectrometer (JEOL
Ltd.), and TGA was performed on a TGA Q500 V6.7
Build 203 (TA Instruments) using a 2910 MDSC V4.4E
(TA Instruments) analyzer under a N2 atmosphere with
heating and cooling rates of 108 minÀ1. UVÀvisible ab-
sorption spectra were measured using a Model S-300
Scinco UVÀvis spectrophotometer, and photolumines-
cence (PL) spectra were recorded using a Shimadzu RF
5301 PC fluorometer. Cyclic voltammetry (CH Instru-
ments 600D) was performed using a 0.10 M solution of
tetrabutylammonium tetrafluoroborate in 1,2-dichloro-
benzene with the analyte present at a concentration of
10À3 M and employing a scan rate of 100 mVsÀ1 at room
temperature under an argon atmosphere. A Pt electrode
was used as the working electrode, and a Pt wire and Ag/
Ag+ electrode were used as the counter and reference
electrodes, respectively. Atomic force microscopy was
performed using a Digital Instruments NanoScope IV op-
erating in the tapping mode in air after annealing at 1508
for 10 min.
1
957.53; purity: 98.7% by HPLC. M_OXCTA: H NMR
(300 MHz, CDCl3, d): 7.62–6.93 (m, 9H), 4.75–3.16 (m,
12H), 2.43–1.98 (m, 9H); 13C NMR (75 MHz, CDCl3, d):
156.14, 155.57, 153.82, 152.65, 151.55, 149.13, 148.63,
147.53, 147.21, 146.64, 145.21, 144.46, 144.35, 143.62,
143.31, 143.02, 142.99, 142.67, 142.12, 142.03, 141.93,
141.35, 140.56, 140.17, 139.75, 139.33, 138.64, 138.57,
130.87, 129.81, 129.26, 128.50, 128.11, 67.46, 62.77, 62.06,
67.78, 66.76, 65.27, 64.21, 46.85, 46.55, 46.13, 45.56, 45.23,
43.83, 43.22, 42.61, 42.39, 21.85, 21.66, 21.35, 21.06;
MALDI-TOF MS (M+1, C87H32): calcd, 1076.25; found,
1075.73; purity: 98.1% by HPLC.
Synthesis of DM_OXCMA, DM_OXCBA, and DM_OXCTA
4,5-Dimethyl o-xylene-substituted fullerene derivatives,
i.e., DM_OXCMA (161 mg, 13.6%), DM_OXCBA
(302 mg, 22.1%), and DM_OXCTA (262 mg, 16.9%),
were prepared from compound 4 via the same procedure
Isr. J. Chem. 2015, 55, 1017 – 1027
ꢀ 2015 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
1025